Individualized Information Sharing Important in All Stages of Cancer Care
the Cancer Therapy Advisor take:
Appropriate, individualized sharing of information for patients with cancer was determined to be important during treatment, at the time of hospital discharge, and in primary care, according to an article published online in the journal European Journal of Cancer Care.
The authors of this study aimed to explore cancer survivors’ experiences regarding information they were given about potential long-term and late effects of pelvic radiotherapy.
Twenty-eight cancer survivors who had received pelvic radiotherapy for a range of cancers (1-11 years prior to the study) were interviewed. Participants from a larger questionnaire survey of patients treated at another hospital were also interviewed.
Results showed the patients acknowledged the potential ability of information to reassure and inform patients, but also identified its ability to produce undesirable effects or raise anxieties about future problems.
Furthermore, the participants identified the importance of the timing, amount of information provided, and context of their situations—value was also placed on information based on personal experience.
Appropriate, individualized sharing of information for patients with cancer was determined to be important during all stages.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer